Earnings summaries and quarterly performance for Nurix Therapeutics.
Executive leadership at Nurix Therapeutics.
Board of directors at Nurix Therapeutics.
Research analysts covering Nurix Therapeutics.
Recent press releases and 8-K filings for NRIX.
Nurix Therapeutics Presents Positive Phase 1 Data for Bexobrutideg in CLL
NRIX
Product Launch
New Projects/Investments
Guidance Update
- Nurix Therapeutics announced new clinical data for bexobrutideg (NX-5948) in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition on December 6, 2025.
- The Phase 1a study demonstrated an objective response rate (ORR) of 83% (including two complete responses), a median progression-free survival (PFS) of 22.1 months, and a median duration of response (DOR) of 20.1 months.
- The 600 mg dose was selected as the recommended Phase 2 dose (RP2D) due to a higher ORR of 83.3% and suggested longer PFS in the randomized Phase 1b cohort, while maintaining a well-tolerated safety profile.
- A Phase 2 clinical trial (DAYBreak-CLL-201) is currently enrolling globally, with a confirmatory Phase 3 trial planned for initiation in H1 2026.
Dec 9, 2025, 11:05 AM
Nurix Therapeutics Highlights Strong Clinical Data for Bexabrutadeg and Pipeline Progress
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics' lead drug, Bexabrutadeg (BexDeg), a BTK degrader, demonstrated an 83% overall response rate (ORR) and a median progression-free survival (PFS) of 22.1 months in phase 1A CLL patients, with the 600 mg dose established as the recommended phase 2 dose.
- The company has initiated its first pivotal single-arm phase 2 trial for BexDeg in triple-exposed CLL patients and plans to start a randomized controlled phase 3 trial in the first half of 2026 for BTKi-exposed patients.
- Nurix strengthened its balance sheet with a $250 million follow-on offering, bringing its cash base to over $650 million and extending its cash runway into 2028.
- The company anticipates multiple new data readouts and IND filings in 2026 for its pipeline programs, including STAT6 and IRAK4 degraders, and a new formulation of BexDeg for I&I indications.
Dec 9, 2025, 1:15 AM
Nurix Therapeutics Provides Update on Bexabrutadeg Clinical Development and Financial Position
NRIX
New Projects/Investments
Revenue Acceleration/Inflection
- Nurix Therapeutics' BTK degrader, Bexabrutadeg (BexDeg), has demonstrated robust clinical activity and an excellent safety profile in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia.
- In CLL, BexDeg achieved an 83% overall response rate (ORR) in Phase 1A patients, with a median progression-free survival (PFS) of 22.1 months, outperforming recent entrants like Pirtobrutinib in a more heavily pretreated patient population.
- The 600 mg dose has been established as the recommended Phase 2 dose, approved by the FDA, EMA, and MHRA, and Nurix has initiated its first pivotal Phase 2 trial for BexDeg.
- The company plans to start a randomized controlled trial in the first half of 2026 and reported a strong financial position with over $650 million in cash, providing a runway into 2028.
Dec 9, 2025, 1:15 AM
Nurix Therapeutics Presents New Clinical Data for Bexobrutideg at ASH Meeting
NRIX
New Projects/Investments
- Nurix Therapeutics presented new clinical data for bexobrutideg (NX-5948) at the 67th American Society of Hematology (ASH) Annual Meeting on December 6, 2025, from its Phase 1a/1b study in patients with relapsed or refractory B-cell malignancies.
- The updated Phase 1a data showed an objective response rate (ORR) of 83% and a median progression-free survival (PFS) of 22.1 months in CLL patients, with a median duration of response (DOR) of 20.1 months.
- Emerging data from the randomized Phase 1b cohort indicated that the 600 mg recommended Phase 2 dose (RP2D) achieved an ORR of 83.3%, compared to 73.7% for the 200 mg dose, and suggested longer progression-free survival.
- Bexobrutideg was well tolerated across all dose levels, with a consistent safety profile observed at the 600 mg RP2D, including no dose-limiting toxicities or Grade 4 infections.
- The company is currently enrolling patients globally for the Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201), with the 600 mg once daily dose selected for further development.
Dec 6, 2025, 2:30 PM
Nurix Therapeutics Provides Update on Degrader Pipeline and Clinical Trials
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics is advancing its lead targeted protein degrader, Bexobrutideg, for oncology and autoimmune diseases, with a Phase 3 randomized confirmatory trial for CLL planned to start in the first half of 2026.
- Bexobrutideg differentiates from inhibitors by completely removing the BTK protein, addressing resistance mutations, and demonstrating a clean proteomic profile with 64-fold selectivity over TEC, which is associated with cardiovascular side effects.
- The company will present new data on Bexobrutideg at the upcoming ASH meeting, including duration of effect, progression-free survival, and the selection of the 600 mg once-daily dose for pivotal studies.
- Nurix estimates the total CLL market for BTK targeted agents to be $9.5 billion per year, with approximately 10,000 new second-line patient prescriptions and 6,000 third-line plus annually in the U.S..
- In its autoimmune pipeline, Nurix is developing a STAT6 degrader (NX3911) with Sanofi, projected for IND filing in 2026, and an IRAK4 degrader with Gilead, currently in Phase 1, with potential data release in 2026.
Dec 3, 2025, 5:30 PM
Nurix Therapeutics Updates on Pipeline Progress and Clinical Trials
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics' lead program, Bexobrutadeg, a BTK degrader, is in pivotal studies for CLL, with a phase three randomized confirmatory trial planned to start in the first half of 2026.
- Bexobrutadeg demonstrates superior selectivity and mutational coverage, including 64-fold selectivity against TEC, a kinase associated with cardiovascular side effects, compared to competitor compounds.
- The company will present new data on Bexobrutadeg at the upcoming ASH meeting, including duration of effect, progression-free survival, and support for the 600 mg once daily dose chosen for pivotal studies.
- Nurix is advancing partnered programs, including a STAT6 degrader (NX3911) with Sanofi in IND enabling studies, with initial clinical development expected in 2026, and an IRAK4 degrader with Gilead in phase one, with potential phase 1 data release in 2026.
- The company highlights a substantial market opportunity in CLL, with the total marketplace for BTK targeted agents valued at $9.5 billion per year and approximately 10,000 new second-line patient prescriptions/starts annually in the US.
Dec 3, 2025, 5:30 PM
Nurix Therapeutics Provides Updates on Clinical Programs and Financial Position
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics (NRIX) plans to present follow-up and longer-term data for Bexobrutideg and NX-5948 at ASH, including duration of therapy and response from Phase 1A, and Phase 1B data. The 600 mg once-a-day dose for Bexobrutideg in CLL has been selected for the pivotal trial with FDA agreement.
- The initial pivotal study for Bexobrutideg in CLL will be a single-arm study targeting triple-exposed patients for accelerated approval, with a broader randomized controlled study planned for the second-line setting.
- The company is developing a new formulation of Bexobrutideg for autoimmune diseases, with an IND anticipated in 2026, and sees significant potential in neuroinflammatory diseases like MS due to its CNS activity.
- Nurix's partnered pipeline includes the IRAK4 degrader (GS-6791) with Gilead in Phase 1 (data expected 2026) and the STAT6 degrader (NX-3911) with Sanofi in IND enabling studies, with valuable opt-in rights for Nurix.
- Nurix recently raised $250 million, bringing its cash reserves to over $650 million and extending its financial runway through the beginning of 2028.
Nov 19, 2025, 11:00 AM
Nurix Therapeutics Details ASH 2025 Data, Pipeline Progress, and Financial Position
NRIX
Product Launch
New Projects/Investments
Guidance Update
- Nurix Therapeutics will present longer-term data for bexobrutideg and NX-5948 at ASH 2025, including duration of response and PFS, with patients on therapy for over two years. The 600 mg once-a-day dose of bexobrutideg has been selected for its pivotal CLL trial with FDA agreement.
- The company is pursuing accelerated approval for bexobrutideg in CLL for triple-exposed patients, with a subsequent randomized control study planned for full approval in the second-line setting, targeting a market of over 10,000 patients per year.
- Nurix's partnered pipeline includes the IRAK4 degrader (GS-6791) with Gilead in Phase I (data expected in 2026) and the STAT6 degrader (NX-3911) with Sanofi in IND-enabling studies, with Nurix holding valuable opt-in rights for co-development and co-commercialization.
- The company's cash reserves stand at over $650 million following a recent $250 million raise, providing a financial runway through the beginning of 2028.
Nov 19, 2025, 11:00 AM
Nurix Therapeutics Advances Bexdeg in CLL and Strengthens Financial Position
NRIX
New Projects/Investments
Guidance Update
- Nurix Therapeutics has initiated pivotal trials for Bexobrutideg (Bexdeg) in Chronic Lymphocytic Leukemia (CLL), demonstrating an 80% response rate in patients with four prior lines of therapy, and selected a 600 mg dose for its accelerated approval trial. A confirmatory Phase III trial is planned for initiation in H1 2026.
- The company will present updated data on Bexdeg at ASH, focusing on duration of response/progression-free survival and further justification for the 600 mg dose.
- Nurix reported a strong financial position with over $650 million in cash, providing a runway through the end of 2027 into 2028, bolstered by a recent $250 million offering.
- Other pipeline advancements include establishing mechanistic proof of concept for the CBL-B program in colorectal and prostate cancer, and progress in partnered programs with Sanofi (STAT6 degrader, expected in healthy volunteers in 2026) and Gilead (IRAK4 degrader in MAD studies).
Nov 13, 2025, 2:20 PM
Nurix Therapeutics Initiates Pivotal DAYBreak Clinical Trial for Bexobrutideg
NRIX
Product Launch
New Projects/Investments
- Nurix Therapeutics, Inc. has initiated the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of bexobrutideg (NX-5948) for patients with relapsed or refractory chronic lymphocytic leukemia (r/r CLL).
- The 600 mg once daily oral dose of bexobrutideg has been cleared by global regulators, including the U.S. FDA, U.K. MHRA, and European Medicines Agency, for pivotal monotherapy trials.
- The DAYBreak study, with its first site activated in October 2025, aims to generate data to support a potential Accelerated Approval submission.
- Nurix plans to initiate a randomized confirmatory Phase 3 trial and a Phase 1b/2 combination study for bexobrutideg in the first half of 2026.
- New preclinical data support bexobrutideg's potential best-in-class BTK degrader profile, demonstrating superior degradation potency, broad coverage of BTK mutations, and exquisite selectivity.
Oct 22, 2025, 1:04 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more